Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
Medical Oncology Branch, National Institutes of Health, Bethesda, MD.
Ciara C
CC
O'Sullivan
Department of Pathology, Georgetown University Medical Center, Washington, DC.
Metin
M
Ozdemirli
Department of Radiology, MedStar Georgetown University Hospital, Washington, DC.
Michael
M
Bazylewicz
Department of Hematology-Oncology, Georgetown University Medical Center, Washington, DC; Lombardi Comprehensive Cancer Center, Washington, DC.
Bruce D
BD
Cheson
D000328:Adult; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D017730:Ki-1 Antigen; D008297:Male; D012008:Recurrence
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin